BlackRock Inc. bought a new position in HUTCHISON CHINA/S (NASDAQ:HCM) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,142,482 shares of the company’s stock, valued at approximately $72,560,000. BlackRock Inc. owned approximately 2.36% of HUTCHISON CHINA/S at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the business. Quantamental Technologies LLC bought a new stake in shares of HUTCHISON CHINA/S in the 4th quarter worth $48,000. Bank of Montreal Can grew its holdings in shares of HUTCHISON CHINA/S by 238.5% in the fourth quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock worth $102,000 after acquiring an additional 3,100 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new stake in shares of HUTCHISON CHINA/S in the fourth quarter worth $154,000. SG Americas Securities LLC bought a new stake in shares of HUTCHISON CHINA/S in the fourth quarter worth $250,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of HUTCHISON CHINA/S in the fourth quarter worth $367,000. 16.57% of the stock is owned by institutional investors and hedge funds.
Several analysts recently commented on the company. Zacks Investment Research raised HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a report on Monday, April 1st. BidaskClub raised HUTCHISON CHINA/S from a “hold” rating to a “buy” rating in a report on Monday, February 25th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. HUTCHISON CHINA/S presently has an average rating of “Buy” and a consensus price target of $26.82.
HUTCHISON CHINA/S Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Recommended Story: Relative Strength Index
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.